Abstract |
The pharmacokinetics of pyrazinamide (Pirilène) and its metabolites are evaluated in ten subjects with hepatic insufficiency, after an oral dose of 19.3 +/- 0.6 mg.kg-1 and the results are compared to those of a group of nine healthy subjects (control group). The results exhibit a marked reduction of the pyrazinamide total clearance (0.48 vs 0.84 ml.min-1.kg-1) and an increase in half-life from 9.19 h to 15.07 h in the patients group. The area under the curve of pyrazinoic acid (the main metabolite) is increased from 97 to 280 mg.h.l-1 with a half-life twice as much as that of the control group. The hepatic insufficiency entails a marked reduction of the common posology as well as a closer survey of the biologic hepatic parameters and of uric acid the renal elimination of which is inhibited by pyrazinoic acid.
|
Authors | C Lacroix, J L Tranvouez, T Phan Hoang, H Duwoos, O Lafont |
Journal | Arzneimittel-Forschung
(Arzneimittelforschung)
Vol. 40
Issue 1
Pg. 76-9
(Jan 1990)
ISSN: 0004-4172 [Print] Germany |
PMID | 2340003
(Publication Type: Journal Article)
|
Chemical References |
- 5-hydroxypyrazinamide
- Pyrazinamide
- pyrazinoic acid
- 5-hydroxypyrazinoic acid
|
Topics |
- Adult
- Chromatography, High Pressure Liquid
- Female
- Half-Life
- Humans
- Liver Cirrhosis
(metabolism)
- Liver Function Tests
- Male
- Pyrazinamide
(analogs & derivatives, blood, metabolism, pharmacokinetics)
|